Сравнение

Glepaglutide vs. Icatibant

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

нет данных

138614-30-9

Молекулярная масса

нет данных

1304.52 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Glepaglutide

As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.

Icatibant

Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Glepaglutide	Icatibant
Германия	Не одобрено	Рецептурный
США	Не одобрено	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Glepaglutide and Icatibant?: Glepaglutide is classified as "Исследования (прочее)", while Icatibant is classified as "Исследования (прочее)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Glepaglutide or Icatibant?: The highest available evidence level is "РКИ на людях" for Glepaglutide and "РКИ на людях" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Glepaglutide and Icatibant in Germany and the United States?: Германия: Glepaglutide — Не одобрено, Icatibant — Рецептурный. США: Glepaglutide — Не одобрено, Icatibant — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Glepaglutide

Icatibant

Германия

Не одобрено

Рецептурный

США

Не одобрено

Рецептурный

Frequently asked questions

What is the difference between Glepaglutide and Icatibant?

Glepaglutide is classified as "Исследования (прочее)", while Icatibant is classified as "Исследования (прочее)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Glepaglutide or Icatibant?

The highest available evidence level is "РКИ на людях" for Glepaglutide and "РКИ на людях" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Glepaglutide and Icatibant in Germany and the United States?

Германия: Glepaglutide — Не одобрено, Icatibant — Рецептурный. США: Glepaglutide — Не одобрено, Icatibant — Рецептурный. These are factual summaries with source and review date on the individual pages.